Who
Goran Ando
Director
Company insider
Files Form 4 as: Director, EyePoint; Director, Cartesian Therapeutics; Director, Enzon Pharmaceuticals.
In numbers
- Trades disclosed
- 50
- Buys
- 2
- Sells
- 0
- Bought
- $96K
- Sold
- $0
- Companies
- 3
- Companies where not an officer
- 3
- First trade
- 3 Jan 2006
- Last trade
- 2 Jan 2026
- Last filed
- 6 Jan 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 2 Jan 2026filed 6 Jan 2026 | EYPT EyePointoption or derivative · Biotechnology | SEC FORM 4 Code A | —41,500 at $0.00 | filing |
| 2 Jan 2026filed 6 Jan 2026 | EYPT EyePointoption or derivative · Biotechnology | SEC FORM 4 Code A | —41,500 at $0.00 | filing |
| 3 Jan 2025filed 7 Jan 2025 | EYPT EyePointoption or derivative · Biotechnology | SEC FORM 4 Code A | —41,500 at $0.00 | filing |
| 21 Aug 2024filed 21 Aug 2024 | EYPT EyePointBiotechnology | SEC FORM 4 Bought | $40K5,000 at $7.95 | filing |
| 5 Jan 2024filed 9 Jan 2024 | EYPT EyePointoption or derivative · Biotechnology | SEC FORM 4 Code A | —23,598 at $0.00 | filing |
| 20 Jun 2023filed 22 Jun 2023 | EYPT EyePointoption or derivative · Biotechnology | SEC FORM 4 Code A | —27,100 at $0.00 | filing |
| 20 Jun 2023filed 22 Jun 2023 | EYPT EyePointoption or derivative · Biotechnology | SEC FORM 4 Code A | —13,500 at $0.00 | filing |
| 9 Feb 2023filed 13 Feb 2023 | EYPT EyePointoption or derivative · Biotechnology | SEC FORM 4 Code M | —3,250 at $0.00 | filing |
| 9 Feb 2023filed 13 Feb 2023 | EYPT EyePointBiotechnology | SEC FORM 4 Code M | —3,250 at $0.00 | filing |
| 2 Jan 2023filed 4 Jan 2023 | RNAC Cartesian Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —75,000 at $0.00 | filing |
| 9 Feb 2022filed 11 Feb 2022 | EYPT EyePointoption or derivative · Biotechnology | SEC FORM 4 Code A | —3,250 at $0.00 | filing |
| 9 Feb 2022filed 11 Feb 2022 | EYPT EyePointoption or derivative · Biotechnology | SEC FORM 4 Code M | —2,750 at $0.00 | filing |
| 9 Feb 2022filed 11 Feb 2022 | EYPT EyePointoption or derivative · Biotechnology | SEC FORM 4 Code A | —12,000 at $0.00 | filing |
| 9 Feb 2022filed 11 Feb 2022 | EYPT EyePointBiotechnology | SEC FORM 4 Code M | —2,750 at $0.00 | filing |
| 3 Jan 2022filed 5 Jan 2022 | RNAC Cartesian Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —40,000 at $0.00 | filing |
| 22 Jun 2021filed 23 Jun 2021 | EYPT EyePointoption or derivative · Biotechnology | SEC FORM 4 Code A | —2,750 at $0.00 | filing |
| 22 Jun 2021filed 23 Jun 2021 | EYPT EyePointoption or derivative · Biotechnology | SEC FORM 4 Code A | —12,000 at $0.00 | filing |
| 30 Mar 2021filed 1 Apr 2021 | RNAC Cartesian Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —40,000 at $0.00 | filing |
| 28 Feb 2021filed 2 Mar 2021 | EYPT EyePointoption or derivative · Biotechnology | SEC FORM 4 Code M | —2,150 at $0.00 | filing |
| 28 Feb 2021filed 2 Mar 2021 | EYPT EyePointBiotechnology | SEC FORM 4 Code M | —2,150 at $0.00 | filing |
News
Eyepoint Pharmaceuticals (NASDAQ:EYPT) Downgraded by Jefferies Financial Group to "Hold"EYPT · tickerreport.com · 19 Oct 2026Critical Review: Eyepoint Pharmaceuticals (NASDAQ:EYPT) and GSK (NYSE:GSK)EYPT · themarketsdaily.com · 11 Oct 2026
0 headlines in the last 90 days name Goran Ando; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.